SG11201703931QA - Non-human animals having a humanized cluster of differentiation 274 gene - Google Patents

Non-human animals having a humanized cluster of differentiation 274 gene

Info

Publication number
SG11201703931QA
SG11201703931QA SG11201703931QA SG11201703931QA SG11201703931QA SG 11201703931Q A SG11201703931Q A SG 11201703931QA SG 11201703931Q A SG11201703931Q A SG 11201703931QA SG 11201703931Q A SG11201703931Q A SG 11201703931QA SG 11201703931Q A SG11201703931Q A SG 11201703931QA
Authority
SG
Singapore
Prior art keywords
differentiation
gene
human animals
humanized
cluster
Prior art date
Application number
SG11201703931QA
Inventor
Elena Burova
Yajun Tang
Ka-Man Venus Lai
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201703931QA publication Critical patent/SG11201703931QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Humanized animals, e.g. knockin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/02Animal zootechnically ameliorated
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
SG11201703931QA 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene SG11201703931QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US201562106525P 2015-01-22 2015-01-22
PCT/US2015/064626 WO2016094481A1 (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Publications (1)

Publication Number Publication Date
SG11201703931QA true SG11201703931QA (en) 2017-06-29

Family

ID=55024286

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703931QA SG11201703931QA (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene
SG10202100792XA SG10202100792XA (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202100792XA SG10202100792XA (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Country Status (23)

Country Link
US (3) US9913461B2 (en)
EP (2) EP3808775B1 (en)
JP (3) JP2018500896A (en)
KR (2) KR102457921B1 (en)
CN (2) CN107257624B (en)
AU (2) AU2015360667B2 (en)
BR (1) BR112017011982A2 (en)
CA (1) CA2968675C (en)
CY (1) CY1123723T1 (en)
DK (1) DK3230320T3 (en)
ES (1) ES2841353T3 (en)
HR (1) HRP20202034T1 (en)
HU (1) HUE052606T2 (en)
IL (3) IL282649B (en)
LT (1) LT3230320T (en)
MX (1) MX2017007636A (en)
PT (1) PT3230320T (en)
RS (1) RS61218B1 (en)
RU (1) RU2711729C2 (en)
SG (2) SG11201703931QA (en)
SI (1) SI3230320T1 (en)
WO (1) WO2016094481A1 (en)
ZA (1) ZA201703263B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016094481A1 (en) * 2014-12-09 2016-06-16 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
AU2016358101B2 (en) 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
KR102487839B1 (en) 2016-02-04 2023-01-12 리제너론 파마슈티칼스 인코포레이티드 Non-human animals with an engineered ANGPTL8 gene
PT3422845T (en) 2016-02-29 2021-08-26 Regeneron Pharma Rodents having a humanized tmprss gene
DK3476865T3 (en) 2016-06-28 2023-12-18 Biocytogen Pharmaceuticals Beijing Co Ltd PROCEDURE FOR CONSTRUCTION OF PD-1 GENE-MODIFIED HUMANIZED ANIMAL MODEL AND USE THEREOF
CN107815466B (en) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 Preparation method and application of humanized gene modified animal model
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (en) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized gene modified animal model
DK3507373T3 (en) 2016-08-31 2023-10-30 Biocytogen Pharmaceuticals Beijing Co Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC PD-L1
MX2019006448A (en) 2016-12-01 2020-02-05 Regeneron Pharma Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging.
CN109666701B (en) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 Construction method and application of PD-1 gene modified humanized animal model
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-1
AU2018375796A1 (en) 2017-11-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TRKB locus
AU2019242586A1 (en) 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
WO2020018511A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
CN110846321B (en) * 2018-08-21 2021-11-19 中国科学院动物研究所 Mutant gene and application thereof in constructing speckled ichthyosis miniature pig model
WO2020081585A1 (en) * 2018-10-15 2020-04-23 The Brigham And Women's Hospital, Inc. The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy
CN109452229B (en) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of caninized PD-1 gene modified animal model
CN109979539B (en) * 2019-04-10 2020-10-02 电子科技大学 Gene sequence optimization method and device and data processing terminal
EP4294180A1 (en) * 2021-02-19 2023-12-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd3 genes
CN112999368A (en) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 Establishment of method for evaluating drug effect by using humanized model

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
DE10211088A1 (en) * 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
DE10161767T1 (en) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotentiating compositions containing an anti-PD-L1 antibody
KR20050084317A (en) * 2002-12-16 2005-08-26 제넨테크, 인크. Transgenic mice expressing human cd20 and/or cd16
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
ATE510020T1 (en) 2003-12-24 2011-06-15 G2 Inflammation Pty Ltd TRANSGENIC NON-HUMAN MAMMAL WITH A POLYNUCLEOTIDE CODING FOR HUMAN-C5AR OR HUMANIZED C5AR
AU2004304665B2 (en) 2003-12-24 2009-03-12 Novo Nordisk A/S Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
CA2943949C (en) 2004-10-06 2020-03-31 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
CA2827654C (en) 2004-10-19 2019-04-02 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
KR102097887B1 (en) 2008-09-26 2020-04-06 다나-파버 캔서 인스티튜트 인크. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
RU2573912C2 (en) 2008-10-08 2016-01-27 Интрексон Корпорейшн Constructed cells, expressing multiple immunomodulators, and thereof application
CN112680475A (en) * 2008-12-18 2021-04-20 伊拉兹马斯大学鹿特丹医学中心 Non-human transgenic animals expressing humanized antibodies and uses thereof
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
RU2425880C2 (en) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
KR101778813B1 (en) * 2009-08-28 2017-09-14 리제너론 파마슈티칼스 인코포레이티드 Antikine antibodies that bind to multiple cc chemokines
JP5874881B2 (en) 2009-10-06 2016-03-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Genetically modified mice and transplantation methods
US20120263692A1 (en) 2009-11-16 2012-10-18 Bertone Alicia L Engineered Xenogeneic Cells for Repair of Biological Tissue
HUE037159T2 (en) * 2009-11-24 2018-08-28 Medimmune Ltd Targeted binding agents against b7-h1
TR201808011T4 (en) * 2009-12-21 2018-06-21 Regeneron Pharma Humanized fc gamma rats.
AU2011237630B2 (en) * 2010-04-06 2016-01-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
MY162984A (en) 2011-02-15 2017-07-31 Regeneron Pharma Humanized m-csf mice
CA3074400A1 (en) * 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
EP3696262A1 (en) 2011-11-23 2020-08-19 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
CN111499755A (en) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 anti-PD-L1 and PD-L2 double-binding antibody single reagents and methods of use thereof
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
EP4011915B8 (en) * 2012-08-21 2023-11-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JP6283031B2 (en) 2012-09-07 2018-02-21 イエール ユニバーシティ Genetically modified non-human animals and uses thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
EP2958990B1 (en) 2013-02-20 2019-10-16 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
DK2958938T3 (en) * 2013-02-20 2019-07-15 Regeneron Pharma Mice expressing humanized T cell co-receptors
US10154658B2 (en) * 2013-02-22 2018-12-18 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
PT3456831T (en) 2013-04-16 2021-09-10 Regeneron Pharma Targeted modification of rat genome
CN103242448B (en) * 2013-05-27 2015-01-14 郑州大学 Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
SG10201811116UA (en) * 2014-06-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
WO2016094481A1 (en) * 2014-12-09 2016-06-16 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
DK3507373T3 (en) 2016-08-31 2023-10-30 Biocytogen Pharmaceuticals Beijing Co Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC PD-L1

Also Published As

Publication number Publication date
EP3808775B1 (en) 2024-04-17
MX2017007636A (en) 2018-03-28
HRP20202034T1 (en) 2021-02-19
AU2021286369A1 (en) 2022-01-20
SI3230320T1 (en) 2021-02-26
RU2711729C2 (en) 2020-01-21
ZA201703263B (en) 2023-02-22
EP3230320A1 (en) 2017-10-18
KR102457921B1 (en) 2022-10-25
US20210105983A1 (en) 2021-04-15
WO2016094481A1 (en) 2016-06-16
US20180160663A1 (en) 2018-06-14
JP7145920B2 (en) 2022-10-03
CY1123723T1 (en) 2022-03-24
LT3230320T (en) 2021-01-11
RU2017123754A (en) 2019-01-10
RS61218B1 (en) 2021-01-29
HUE052606T2 (en) 2021-05-28
KR20210130251A (en) 2021-10-29
CN113412818B (en) 2022-11-04
CA2968675C (en) 2023-10-17
DK3230320T3 (en) 2021-01-11
CA2968675A1 (en) 2016-06-16
CN107257624B (en) 2021-07-13
IL275864A (en) 2020-08-31
IL275864B (en) 2021-05-31
AU2015360667A1 (en) 2017-06-08
IL252695B (en) 2020-07-30
BR112017011982A2 (en) 2018-01-16
ES2841353T3 (en) 2021-07-08
AU2015360667B2 (en) 2021-09-23
RU2017123754A3 (en) 2019-06-24
IL252695A0 (en) 2017-08-31
KR102316842B1 (en) 2021-10-25
US9913461B2 (en) 2018-03-13
SG10202100792XA (en) 2021-03-30
CN107257624A (en) 2017-10-17
PT3230320T (en) 2021-01-08
KR20170101910A (en) 2017-09-06
JP2022184973A (en) 2022-12-13
US20160157469A1 (en) 2016-06-09
JP2018500896A (en) 2018-01-18
EP3808775A1 (en) 2021-04-21
CN113412818A (en) 2021-09-21
IL282649A (en) 2021-06-30
JP2021003130A (en) 2021-01-14
EP3230320B1 (en) 2020-10-07
IL282649B (en) 2022-07-01
US10881086B2 (en) 2021-01-05

Similar Documents

Publication Publication Date Title
IL286403A (en) Non-human animals having a humanized cluster of differentiation 47 gene
IL282649A (en) Non-human animals having a humanized cluster of differentiation 274 gene
IL287519A (en) Non-human animals having a humanized programmed cell death 1 gene
HK1253683A1 (en) Non-human animals having a humanized lymphocyte-activation gene 3